Abstract. Polycomb group proteins control the transcriptional memory of cells by maintaining the stable silencing of specific sets of genes through chromatin modifications. Polycomb group protein complexes control gene repression through recruitment of histone deacetylase. This recruitment leads to trimethylation of Lys 27 of histone H3 (H3K27). Histone H3K27 trimethylation is a property of stably silenced heterochromatin. EZH2 and BMI-1 are pivotal components of polycomb group protein complexes. Increased EZH2 levels have been found in several malignancies and reported as a molecular biomarker of poor prognosis. Similarly, BMI-1 has also been found to be associated with malignant transformation. In addition, inhibition of EZH2 or BMI-1 inhibits the growth of various types of malignancies. The expression of BMI-1 and EZH2 in human osteosarcoma has not been clearly determined. We examined the potential involvement of aberrant polycomb group protein expression in the pathogenesis of osteosarcoma. Real-time PCR revealed that expression of EZH2 in 143B, HOS, NOS-1 and Saos2 was increased compared to normal osteoblasts. BMI-1 was also up-regulated in 143B, HOS and NOS-1. Expression of EZH2 and BMI-1 were up-regulated in osteosarcoma patient biopsy specimens compared to normal bone. Immunohistochemical examinations showed that EZH2 and BMI-1 were up-regulated in osteosarcoma cells and that trimethylation of histone H3K27 was increased. We examined the effects of knock down of EZH2 and BMI-1 by shRNA. Unexpectedly, the knock-down of EZH2 and BMI-1 did not prevent osteosarcoma growth either in vitro or in vivo. Our findings suggest that EZH2 and BMI-1 may be tumorassociated antigens of osteosarcoma, but are not useful molecular targets of osteosarcoma treatment.
Introduction
Osteosarcoma is the most common primary bone cancer occurring mainly in children (1) . Standard treatment involves the use of 'up-front' multi-agent chemotherapy, definitive surgery of the primary tumor and postoperative chemotherapy. In recent years, great effort has been made aiming at elucidating the molecular events underpinning the biology of osteosarcoma including dysregulation of cell division and apoptotic processes. Although such dysregulation may constitute a potent source of new therapeutic targets, the molecular mechanisms of regulation of osteosarcoma cell proliferation are largely unknown.
Polycomb group (PcG) proteins control the transcriptional memory of cells by maintaining the stable silencing of specific sets of genes through chromatin modifications (2) . Two distinct and evolutionarily conserved PcG complexes have been identified, consisting of various PcG proteins and non-PcG proteins. The polycomb repressive complex 1 (PRC1) contains the BMI-1, MEL-18, RING1, HPH and HPC PcG proteins, while the polycomb repressive complex 2 (PRC2) contains the EZH2, EED, YY1 and SUZ PcG proteins (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . EZH2 is a histone methyltransferase associated with transcriptional repression. EZH2 catalyzes trimethylation of histone H3 at lysine 27 (H3K27) (16) (17) (18) (19) .
Recent findings have linked deregulated expression of human PcG genes to malignant transformation, loss of differentiation in tumor cells, and metastatic behavior (20) . Increased EZH2 levels have been found in several epithelial tumors (21) (22) (23) (24) (25) (26) and in various hematological malignancies (27) (28) (29) . Similarly, BMI-1 has also been associated with malignant transformation (23, 27, (30) (31) (32) (33) (34) (35) (36) (37) (38) . The expression of BMI-1 and EZH2 in human osteosarcoma cell lines and osteosarcoma patient specimens have not been well defined. To explore the potential involvement of aberrant PcG expression in the pathogenesis of osteosarcoma, we investigated the expression of EZH2 and BMI-1 in osteosarcoma cell lines and patient samples. We next examined the status of trimethylation of H3K27. In addition, we examined the effect of the knock-down of EZH2 and BMI-1 by shRNA in vitro and in vivo. Animal experiments. shRNA-transfected 143B cells (1x10 5 ) were mixed with collagen gel in a 1:1 volume and inoculated subcutaneously in 5-week-old nude mice. Tumor size was measured, and tumor volume was calculated using the formula LW 2 /2 (with L and W representing the length and width of tumors). All experimental procedures were performed in compliance with the guiding principles for the Care and Use of Animals described in the American Journal of Physiology and with the Guidelines established by the Institute of Laboratory Animal Sciences, Faculty of Medicine, Kagoshima University. All efforts were made to minimize animal suffering, to reduce the number of animals used and to utilize possible alternatives to in vivo techniques.
Data analysis. Each sample was analyzed in triplicate and experiments were repeated three times. In figures the error bar means standard error. Data were analyzed by the STASTISCA (StatSoft, OK, USA). Differences between mean values were evaluated by the unpaired t-test and differences in frequencies were evaluated by Fisher's exact test. Results were considered statistically significant at P<0.05.
Results

Overexpression of EZH2 and BMI-1 in osteosarcoma.
RT-PCR was performed to examine the expression of EZH2 and BMI-1 in osteosarcoma cell lines. RT-PCR revealed that NOS-1, HOS and 143B osteosarcoma cell lines expressed EZH2 more strongly than normal human osteoblasts (NHOst) (Fig. 1A) . More sensitive real-time PCR analyses revealed that expression of EZH2 in 143B, HOS, NOS-1 and Saos2 was increased 13-, 11-, 4.9-and 4.4-fold, respectively (Fig. 1B) . RT-PCR revealed that NOS-1, HOS and 143B osteosarcoma cell lines expressed BMI-1 more strongly than NHOst (Fig. 1C) . Real-time PCR revealed that expression of BMI-1 in 143B, HOS and NOS-1 was increased 6.7-, 3.7-and 3.7-fold, respectively, while that in Saos2 did not change appreciably (Fig. 1D) . We next examined the expression of EZH2 and BMI-1 in osteosarcoma patient biopsy samples. RT-PCR revealed that 3 osteosarcoma patient samples expressed EZH2 more strongly than normal bone tissue (Fig. 1E) . Real-time PCR revealed that expression of EZH2 in patient samples was increased 1.4-to 4.2-fold (Fig. 1F) . RT-PCR revealed that 3 osteosarcoma patient samples expressed BMI-1 more strongly than normal bone (Fig. 1G) . Real-time PCR revealed that expression of BMI-1 in patient samples increased 4.5-to 9.4-fold (Fig. 1H) . To extend these findings, we performed immunohistochemistry for EZH2 and BMI-1 examination revealed that osteosarcoma cell lines and osteosarcoma patient samples expressed EZH2 and BMI-1 more strongly than normal bone tissue ( Fig. 2A and B) . EZH2 and BMI-1 were localized in the nucleus of osteosarcoma cells ( Fig. 2A  and B) . These findings showed that EZH2 and BMI-1 are overexpressed in osteosarcomas.
Histone H3-K27 is trimethylated in osteosarcoma. To determine if overexpression of polycomb proteins promoted histone H3K27 trimethylation, we performed immunohistochemical examination using trimethylated histone H3K27-specific antibody. Histone H3K27 was found to be trimethylated more strongly in osteosarcoma cells lines and osteosarcoma patient samples than in normal osteoblasts and bone tissue (Fig. 2C) .
Knock-down of overexpressed EZH2 and BMI-1 does not prevent osteosarcoma growth in vitro or in vivo.
It has been reported that overexpression of EZH2 or BMI-1 promotes malignant transformation (21, 36, 38, (40) (41) (42) (43) (44) (45) (46) (47) . In addition, inhibition of EZH2 or BMI-1 inhibits growth of various types of malignancies (38, 41, 43, 45, 46) . To determine whether knock-down of EZH2 and BMI-1 prevents osteosarcoma growth, we examined the effects of EZH2 and BMI-1 shRNA. We used 143B and HOS, which strongly express EZH2 and BMI-1. Real-time PCR revealed that shRNA effectively knocked-down EZH2 and BMI-1 (Fig. 3A) . 143B and HOS were transfected with EZH2 shRNA, BMI-1 shRNA and EZH2 shRNA plus BMI-1 shRNA. Unexpectedly, MTT assay revealed that the knock-down of EZH2, BMI-1 and EZH2 plus BMI-1 did not prevent osteosarcoma growth in vitro (Fig. 3B-D) . To confirm the effects of EZH2 and BMI-1 knock-down, we examined xenograft models. Nude mice were inoculated with control shRNA-transfected 143B cells, EZH2 shRNA-transfected 143B cells and BMI-1-shRNA-transfected cells intradermally and tumor sizes were measured. Tumor sizes did not significantly differ among these three groups (Fig. 4) .
Discussion
The PcG genes encode a family of evolutionarily conserved regulators that were discovered in Drosophila as repressors of homoeotic genes, which are involved in establishing body segmentation patterns during development. In mammalian systems, PcG proteins regulate genes involved in development and differentiation via epigenetic mechanisms. Transcriptional profiling of human tumor samples holds significant promise for the advancement of cancer therapy, both in terms of improving diagnosis as well as predicting patient responses to treatment. Recently, an RNA expression signature associated with 'stem-cell-ness', based partly on PcGs-driven transcriptional changes, was postulated to predict poor therapeutic outcome in patients with various types of cancers (48) . Although these claims await further validation, they suggest that levels of PcGs expression might prove valuable as prognostic markers, particularly because EZH2 and BMI-1 overexpression appears to be tightly correlated with poor prognosis in various types of cancers (49, 50) . BMI-1 was originally identified as an oncogene (8) . BMI-1 up-regulation induces development of B-and T-cell lymphomas (7, 41, 42) . In this study, we found that EZH2 and BMI-1 RNAs are up-regulated in osteosarcoma cell lines and patient samples, following the study of overexpression of EZH2 in the U2OS human osteosarcoma cell line (51). Steele et al reported that CD8 + T-cell epitopes derived from EZH2 and BMI-1 elicited T-cell responses as assessed by IFN-Á release confirming the presence of CD8 responses against these proteins in patients with cancer (52) . These findings suggest that EZH2 and BMI-1 may be useful targets for cancer immunotherapy of osteosarcoma.
The PRC2 containing EZH2 controls gene repression through recruitment of histone deacetylase. This recruitment leads to local chromatin deacetylation and subsequent trimethylation of Lys 27 of histone H3 (H3K27). Histone H3K27 trimethylation is a property of stably silenced heterochromatin. The PRC1 complex containing BMI-1 subsequently binds to histone H3K27, suppresses gene expression and contributes to the maintenance of epigenetic memory (53) . In this study, we found that histone H3K27 was trimethylated both in osteosarcoma cell lines and patient samples. These findings suggest the possibility that overexpressed EZH2 and BMI-1 are functionally active and promote histone H3K27 trimethylation in osteosarcoma as in stem cells and other types of cancer cells (45, 54, 55) . In addition, trimethylated histone H3K27 suppresses target gene expression via epigenetic regulation (45, 55, 56) . The gene suppression may contribute to the pathogenesis of osteosarcoma. BMI-1 represses the transcription of cell cycle repressors encoded by the ink4a locus (41,57-59). Although PcG proteins are generally recognized as suppressors of target gene transcription, Shi et al reported that EZH2 enhances the transcription of c-myc and cyclin D1 (60) . We previously found that transcription of c-myc is activated and expression of the ink4a locus are suppressed in osteosarcoma (61) . These findings suggest that these genes may be targets of EZH2 and BMI-1 in osteosarcoma.
It has been reported that overexpression of EZH2 or BMI-1 promotes malignant transformation (21, 36, 38, (40) (41) (42) (43) (44) (45) (46) (47) 49) . In addition, inhibition of EZH2 or BMI-1 inhibits growth of various types of malignancies (38, (41) (42) (43) 45, 46, 49) . These findings suggest that EZH2 and BMI-1 play roles in regulating cell proliferation and survival and that EZH2 or BMI-1 may be useful as molecular targets in various types of malignancies. In fact, pharmacologic interference of EZH2 function induces selective apoptosis of cancer cells but not normal cells (62) . In the present study, we examined the effect of EZH2 and BMI-1 knock-down in osteosarcoma and found unexpectedly that EZH2 or BMI-1 knock-down by shRNA did not prevent osteosarcoma growth in vitro or in vivo. These findings are contrary to those reported in previous studies. Two groups reported that although PcG protein overexpression appeared to be correlated with poor prognosis for some types of malignancies, low BMI-1 expression was correlated with poor prognosis of endometrial carcinomas and malignant melanocytic lesion (63, 64) . These studies suggest that osteosarcoma may be included among these types of malignancies. In addition, McGarvey et al reported that EZH2 knock-down results in increased expression of unmethylated and basally expressing genes but not of completely silenced and hypermethylated tumor suppressor genes (65) . These findings suggest that important regulator genes for osteosarcoma growth may be hypermethylated. BMI-1 co-overexpression with other inducers, such as H-RAS, hTERT and p16 INK4a shRNA, resulted in efficient malignant transformation (36, 40, 41, 44) . These findings in turn suggest that other factors might be regulated in addition to BMI-1 to suppress osteosarcoma growth. Taken together, these findings suggest that inhibition of PcG proteins may not be useful for treatment of some other malignancies in addition to osteosarcoma.
In conclusion, we found that EZH2 and BMI-1 are upregulated in osteosarcoma. EZH2 and BMI-1 may be useful targets for cancer immunotherapy of osteosarcoma, although knock-down of EZH2 and BMI-1 could not prevent osteosarcoma growth. Further investigation of the functions of EZH2 and BMI-1 in osteosarcoma is needed. 
